A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

NCT01624259 on ClinicalTrials.gov · last registry update 2014-10-09

Finished November 2013, after enrolling 599 people. Primary outcome, as filed: Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 599
Started: 2012-06
Primary completion: 2013-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.